Advances in the progress of monoclonal antibodies for rabies

Hum Vaccin Immunother. 2022 Dec 31;18(1):2026713. doi: 10.1080/21645515.2022.2026713. Epub 2022 Feb 16.

Abstract

Rabies is a highly fatal zoonotic disease caused by the rabies virus invading the central nervous system. When suspected of exposure to the rabies virus, post-exposure prophylaxis should be administered as soon as possible. Monoclonal antibodies (mAbs) neutralizing the rabies virus could be better in human rabies post-exposure prophylaxis than equine or human rabies immune globulin in terms of supply, cost, and efficacy. This article reviews anti-rabies mAbs produced by multiple techniques, and the results of clinical trials for anti-rabies mAbs cocktails recognizing non-overlapping epitopes are also discussed.

Keywords: Rabies virus; antibody cocktail; antibody library; glycoprotein; monoclonal antibody.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Neutralizing
  • Antibodies, Viral / therapeutic use
  • Antineoplastic Agents, Immunological* / therapeutic use
  • Horses
  • Neutralization Tests
  • Post-Exposure Prophylaxis / methods
  • Rabies Vaccines*
  • Rabies virus*
  • Rabies* / prevention & control

Substances

  • Antibodies, Monoclonal
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Antineoplastic Agents, Immunological
  • Rabies Vaccines

Grants and funding

The author(s) reported that there is no funding associated with the work featured in this article.